AbbVie Inc. has completed an $8 billion underwritten public offering of senior notes, comprising various floating and fixed-rate instruments with maturities ranging from 2028 to 2066. This substantial debt issuance increases the company's long-term interest obligations and provides significant liquidity for potential strategic acquisitions or debt refinancing.
